213 related articles for article (PubMed ID: 30867224)
21. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
[TBL] [Abstract][Full Text] [Related]
22. microRNA and circRNA in Parkinson's Disease and atypical parkinsonian syndromes.
Bougea A; Stefanis L
Adv Clin Chem; 2023; 115():83-133. PubMed ID: 37673523
[TBL] [Abstract][Full Text] [Related]
23. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
24. Free-water imaging in Parkinson's disease and atypical parkinsonism.
Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
[TBL] [Abstract][Full Text] [Related]
25. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.
Hellwig S; Amtage F; Kreft A; Buchert R; Winz OH; Vach W; Spehl TS; Rijntjes M; Hellwig B; Weiller C; Winkler C; Weber WA; Tüscher O; Meyer PT
Neurology; 2012 Sep; 79(13):1314-22. PubMed ID: 22914831
[TBL] [Abstract][Full Text] [Related]
26. Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.
van Rumund A; Aerts MB; Esselink RAJ; Meijer FJA; Verbeek MM; Bloem BR
BMC Neurol; 2018 May; 18(1):69. PubMed ID: 29764386
[TBL] [Abstract][Full Text] [Related]
27. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
28. Neurodegeneration, oxidative stress and lipid metabolism plasma biomarkers to differentiate Parkinson's disease from atypical parkinsonian syndromes.
Schneider V; Vejux A; Nury T; Dupont G; Pais de Barros JP; Lakomy D; Lizard G; Moreau T
Rev Neurol (Paris); 2023 Nov; 179(9):961-966. PubMed ID: 37328356
[TBL] [Abstract][Full Text] [Related]
29. Incidence of Parkinson's disease and atypical parkinsonism: Russian population-based study.
Winter Y; Bezdolnyy Y; Katunina E; Avakjan G; Reese JP; Klotsche J; Oertel WH; Dodel R; Gusev E
Mov Disord; 2010 Feb; 25(3):349-56. PubMed ID: 20108378
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.
Fujita H; Suzuki K; Numao A; Watanabe Y; Uchiyama T; Miyamoto T; Miyamoto M; Hirata K
PLoS One; 2016; 11(11):e0165869. PubMed ID: 27812167
[TBL] [Abstract][Full Text] [Related]
31. Transcranial sonography for the discrimination of idiopathic Parkinson's disease from the atypical parkinsonian syndromes.
Bouwmans AE; Vlaar AM; Srulijes K; Mess WH; Weber WE
Int Rev Neurobiol; 2010; 90():121-46. PubMed ID: 20692498
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls.
Marques TM; van Rumund A; Bruinsma IB; Wessels HJCT; Gloerich J; Esselink RAJ; Bloem BR; Kuiperij HB; Verbeek MM
Mol Neurobiol; 2019 Jul; 56(7):5067-5074. PubMed ID: 30465235
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions.
Magdalinou N; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1065-75. PubMed ID: 24691581
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O
Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes.
Georgiopoulos C; Davidsson A; Engström M; Larsson EM; Zachrisson H; Dizdar N
J Neurol; 2015 Sep; 262(9):2154-63. PubMed ID: 26122543
[TBL] [Abstract][Full Text] [Related]
36. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
37. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes.
Bech S; Hjermind LE; Salvesen L; Nielsen JE; Heegaard NH; Jørgensen HL; Rosengren L; Blennow K; Zetterberg H; Winge K
Parkinsonism Relat Disord; 2012 Jan; 18(1):69-72. PubMed ID: 21873100
[TBL] [Abstract][Full Text] [Related]
38. Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT.
Takaya S; Sawamoto N; Okada T; Okubo G; Nishida S; Togashi K; Fukuyama H; Takahashi R
Parkinsonism Relat Disord; 2018 Feb; 47():15-21. PubMed ID: 29157745
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
